SCHEMBL699963

SCHEMBL699963

COC(=O)c1cccc(-c2ccc(C(C)=O)o2)c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.54
POLB P06746 2/20 0.54
MAPT P10636 1/20 0.54
BLM P54132 1/20 0.54
KMT2A Q03164 1/20 0.54
SAE1 Q9UBE0 1/20 0.54
UBA2 Q9UBT2 1/20 0.54
PRMT1 Q99873 1/20 0.54
PIK3CG P48736 1/20 0.52
PRKDC P78527 1/20 0.49
HPGD P15428 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
TP53 P04637 1/20 0.49
RAC1 P63000 1/20 0.48
CA12 O43570 2/20 0.48
CA9 Q16790 2/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
LOXL2 Q9Y4K0 1/20 0.48
FAAH O00519 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13269280 0.88 NR4A1 (0.60) ALDH1A1POLBMAPTBLMKMT2A
SCHEMBL3056404 0.87 ALDH1A1 (0.53) ALDH1A1POLBMAPTBLMKMT2A
SCHEMBL700838 0.85 POLB (0.60) ALDH1A1POLBMAPTKMT2ASAE1
SCHEMBL14363093 0.84 ALDH1A1 (0.58) ALDH1A1POLBMAPTBLMKMT2A
SCHEMBL702364 0.81 MAPT (0.51) ALDH1A1POLBMAPTKMT2AHPGD
SCHEMBL17348229 0.79 CA12 (0.60) ALDH1A1CA12CA9CA1CA2
SCHEMBL13078464 0.79 SLC9A1 (0.67) ALDH1A1MAPTKMT2AHPGDSMN1; SMN2
SCHEMBL3005513 0.79 NR4A1 (0.63) ALDH1A1POLBMAPTKMT2ASAE1
SCHEMBL67941 0.79 CA12 (0.68) POLBCA12CA9CA1CA2
SCHEMBL30175778 0.78 ALDH1A1 (0.57) ALDH1A1POLBKMT2AHPGDNR4A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-20120190669-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2012-07-26 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
US-8124649-B2 Oxindole compounds CYLENE PHARMACEUTICALS, INC. (US) 2012-02-28 US disclosed
CN-102137866-A Oxindole compounds CYLENE PHARMACEUTICALS INC 2011-07-27 CN disclosed
EP-2307421-A1 OXINDOLE COMPOUNDS Cylene Pharmaceuticals, Inc. (US) 2011-04-13 EP disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
US-20100041635-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. 2010-02-18 US disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed
WO-2010002933-A1 OXINDOLE COMPOUNDS CYLENE PHARMACEUTICALS, INC. (US) 2010-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041635-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 ALDH1A1 2525/4885POLB 2906/4885MAPT 2199/4885
US-20120190669-A1 OXINDOLE COMPOUNDS FLT3, PIM1, PIM2 ALDH1A1 2525/4885POLB 2906/4885MAPT 2199/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.